OncoMatch/Clinical Trials/NCT07032285
Cirtuvivint in Selected Advanced Soft-Tissue Sarcomas
Is NCT07032285 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cirtuvivint for soft tissue sarcoma (sts).
Treatment: Cirtuvivint — The study is a Phase 2 clinical trial of the drug cirtuvivint as a second-line treatment for advanced soft tissue sarcomas. The study is being conducted in Spain and is expected to enroll approximately 25 patients in total. The primary objective of this Phase 2 study is to evaluate the efficacy of treatment with cirtuvivint. Cirtuvivint is an anti-cancer medication developed by the U.S. company Biosplice Therapeutics, Inc. This drug is an inhibitor of the enzymes CLK1-4 and DYRK1-4 (molecules involved in the cell cycle) and is administered as oral tablets. This product is still under investigation and has not yet been approved in Europe.
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anthracycline
Patients should have received at least anthracyclines previously unless not indicated (SFT)
Cannot have received: CLK inhibitor
Previous treatment with CLK inhibitors
Cannot have received: other anti-cancer therapy or investigational product
Patients who have received any other anti-cancer therapy or investigational product in the last 28 days prior to enrollment
Lab requirements
Blood counts
Absolute neutrophil count ≥1,500/mm³; Platelet count ≥100,000/mm³
Kidney function
Creatinine ≤1.5 mg/dL
Liver function
AST and ALT ≤2.5 times upper limit of normal; Bilirubin ≤1.5 mg/dL
Cardiac function
Left ventricular ejection fraction ≥50% by echocardiogram or MUGA scan
Adequate hepatic, renal, cardiac, and hematologic function. Laboratory tests as follows: Absolute neutrophil count ≥1,500/mm³; Platelet count ≥100,000/mm³; Bilirubin ≤1.5 mg/dL; AST and ALT ≤2.5 times upper limit of normal; Creatinine ≤1.5 mg/dL. Left ventricular ejection fraction ≥50% by echocardiogram or MUGA scan.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify